USCWA
PCRX icon

U.S. Capital Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$38.6K – 1259
2022
Q4 		$38.6K Buy
+1,000
New +$48.7K ﹤0.01% 942

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

U.S. Capital Wealth Advisors's PCRX Position: Q1 2023 in Review

U.S. Capital Wealth Advisors sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 1,000 shares — an estimated $38.6K sold.

U.S. Capital Wealth Advisors first reported a position in PCRX in Q4 2022 and held it in 1 quarter. The position peaked at $38.6K in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • U.S. Capital Wealth Advisors reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
  • U.S. Capital Wealth Advisors sold 1,000 Pacira BioSciences shares in Q1 2023, an estimated $38.6K.
  • U.S. Capital Wealth Advisors first reported a position in Pacira BioSciences in Q4 2022 and held it in 1 quarter.
  • U.S. Capital Wealth Advisors's Pacira BioSciences position peaked at $38.6K in Q4 2022.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2023, filed 11 May 2023.